KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

KALV Stock Forecast

KalVista Pharmaceuticals stock forecast is as follows: an average price target of $22.67 (represents a 143.24% upside from KALV’s last price of $9.32) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

KALV Price Target

The average price target for KalVista Pharmaceuticals (KALV) is $22.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $20.00. This represents a potential 143.24% upside from KALV's last price of $9.32.

KALV Analyst Ratings

Buy

According to 4 Wall Street analysts, KalVista Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KALV stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

KalVista Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 05, 2024	Serge Belanger	Needham	$28.00	$11.25	148.89%	200.43%
Sep 06, 2024	Andrew Fein	H.C. Wainwright	$20.00	$12.87	55.40%	114.59%
Sep 06, 2024	Joseph Schwartz	Leerink Partners	$20.00	$12.87	55.40%	114.59%
Jul 08, 2022	-	Needham	$38.00	$10.98	246.08%	307.73%

Row per page

Go to

The latest KalVista Pharmaceuticals stock forecast, released on Nov 05, 2024 by Serge Belanger from Needham, set a price target of $28.00, which represents a 148.89% increase from the stock price at the time of the forecast ($11.25), and a 200.43% increase from KALV last price ($9.32).

KalVista Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	1	3	3
Avg Price Target	$28.00	$22.67	$22.67
Last Closing Price	$9.32	$9.32	$9.32
Upside/Downside	200.43%	143.24%	143.24%

In the current month, the average price target of KalVista Pharmaceuticals stock is $28.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 200.43% increase as opposed to KalVista Pharmaceuticals's last price of $9.32. This month's average price target is up 23.51% compared to last quarter, and up 23.51% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 06, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 06, 2024	Leerink Partners	Outperform	Outperform	Hold
Feb 03, 2023	SVB Leerink	Outperform	Outperform	Hold
Jul 08, 2022	SVB Leerink	Outperform	Outperform	Hold
Jul 08, 2022	Needham	Buy	Buy	Hold

Row per page

Go to

KalVista Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave KALV a "Buy" rating, the same as its previous rate.

KalVista Pharmaceuticals Financial Forecast

KalVista Pharmaceuticals Revenue Forecast

	May 26	Jan 26	Oct 25	Jul 25	May 25	Jan 25	Oct 24	Jul 24	May 24	May 21	Jan 21	Oct 20	Jul 20	May 20	Jan 20	Oct 19	Jul 19	May 19	Jan 19	May 18	Oct 17	May 16	May 15
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.58M	$3.92M	$3.37M	-	$3.89M	-	$1.13M	-	-
Avg Forecast	$28.34M	$17.00M	$11.34M	-	$4.20M	$18.64M	$518.00K	-	$4.46M	$420.00K	$1.20M	$625.00K	$1.50M	$1.90M	$10.08M	$3.27M	$3.22M	$4.03M	$4.25M	$618.16K	$115.69K	$7.40K	$266.76K
High Forecast	$50.68M	$30.41M	$20.27M	-	$7.50M	$33.33M	$926.32K	-	$7.98M	$504.00K	$1.20M	$625.00K	$1.50M	$1.90M	$10.08M	$3.27M	$3.22M	$4.03M	$4.25M	$741.79K	$138.82K	$8.88K	$320.12K
Low Forecast	$6.00M	$3.60M	$2.40M	-	$888.54K	$3.95M	$109.68K	-	$944.37K	$336.00K	$1.20M	$625.00K	$1.50M	$1.90M	$10.08M	$3.27M	$3.22M	$4.03M	$4.25M	$494.53K	$92.55K	$5.92K	$213.41K
# Analysts	2	2	1	-	1	4	1	-	1	14	10	10	7	12	7	6	3	3	6	9	17	8	19
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.16%	1.20%	1.05%	-	0.91%	-	9.74%	-	-

KalVista Pharmaceuticals's average Quarter revenue forecast for May 20 based on 12 analysts is $1.90M, with a low forecast of $1.90M, and a high forecast of $1.90M. KALV's average Quarter revenue forecast represents a 20.21% increase compared to the company's last Quarter revenue of $1.58M (Jan 20).

KalVista Pharmaceuticals EBITDA Forecast

	May 26	Jan 26	Oct 25	Jul 25	May 25	Jan 25	Oct 24	Jul 24	May 24	May 21	Jan 21	Oct 20	Jul 20	May 20	Jan 20	Oct 19	Jul 19	May 19	Jan 19	May 18	Oct 17	May 16	May 15
# Analysts	2	2	1	-	1	4	1	-	1	14	10	10	7	12	7	6	3	3	6	9	17	8	19
EBITDA	-	-	-	-	-	-	-	-	-	-	$-12.82M	$-12.62M	$-14.75M	-	$-12.58M	$-9.59M	$-8.85M	-	$-6.80M	-	$-5.97M	-	-
Avg Forecast	$5.67M	$3.40M	$2.27M	-	$839.31K	$3.73M	$103.60K	-	$892.05K	$-13.87M	$240.00K	$125.00K	$300.00K	$-9.91M	$2.02M	$653.23K	$644.20K	$-5.16M	$850.60K	$-8.25M	$-5.56M	$-4.21M	$-164.52M
High Forecast	$10.14M	$6.08M	$4.05M	-	$1.50M	$6.67M	$185.26K	-	$1.60M	$-11.10M	$240.00K	$125.00K	$300.00K	$-7.93M	$2.02M	$653.23K	$644.20K	$-4.13M	$850.60K	$-6.60M	$-4.45M	$-3.37M	$-131.61M
Low Forecast	$1.20M	$720.10K	$480.08K	-	$177.71K	$789.32K	$21.93K	-	$188.87K	$-16.65M	$240.00K	$125.00K	$300.00K	$-11.90M	$2.02M	$653.23K	$644.20K	$-6.20M	$850.60K	$-9.91M	$-6.67M	$-5.05M	$-197.42M
Surprise %	-	-	-	-	-	-	-	-	-	-	-53.43%	-100.99%	-49.18%	-	-6.24%	-14.68%	-13.74%	-	-8.00%	-	1.07%	-	-

undefined analysts predict KALV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than KalVista Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

KalVista Pharmaceuticals Net Income Forecast

	May 26	Jan 26	Oct 25	Jul 25	May 25	Jan 25	Oct 24	Jul 24	May 24	May 21	Jan 21	Oct 20	Jul 20	May 20	Jan 20	Oct 19	Jul 19	May 19	Jan 19	May 18	Oct 17	May 16	May 15
# Analysts	2	2	1	-	1	4	1	-	1	14	10	10	7	12	7	6	3	3	6	9	17	8	19
Net Income	-	-	-	-	-	-	-	-	-	-	$-10.05M	$-10.43M	$-10.81M	-	$-9.29M	$-5.90M	$-7.34M	-	$-3.96M	-	$-4.99M	-	-
Avg Forecast	$-24.97M	$-32.83M	$-34.67M	$-40.69M	$-37.25M	$-29.92M	$-42.86M	$-42.30M	$-32.95M	$-10.87M	$-27.54M	$-31.04M	$-27.66M	$-10.22M	$-12.09M	$-25.43M	$-28.51M	$-5.30M	$-20.71M	$-8.33M	$-5.60M	$-4.29M	$-197.56M
High Forecast	$617.89K	$812.42K	$858.19K	$1.01M	$921.93K	$51.56M	$-42.40M	$1.05M	$815.43K	$-8.70M	$-27.54M	$-31.04M	$-27.66M	$-8.18M	$-12.09M	$-25.43M	$-28.51M	$-4.24M	$-20.71M	$-6.67M	$-4.48M	$-3.43M	$-158.05M
Low Forecast	$-50.55M	$-66.46M	$-70.21M	$-82.38M	$-75.42M	$-68.11M	$-43.80M	$-85.65M	$-66.71M	$-13.05M	$-27.54M	$-31.04M	$-27.66M	$-12.26M	$-12.09M	$-25.43M	$-28.51M	$-6.36M	$-20.71M	$-10.00M	$-6.72M	$-5.14M	$-237.07M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.36%	0.34%	0.39%	-	0.77%	0.23%	0.26%	-	0.19%	-	0.89%	-	-

KalVista Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KALV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

KalVista Pharmaceuticals SG&A Forecast

	May 26	Jan 26	Oct 25	Jul 25	May 25	Jan 25	Oct 24	Jul 24	May 24	May 21	Jan 21	Oct 20	Jul 20	May 20	Jan 20	Oct 19	Jul 19	May 19	Jan 19	May 18	Oct 17	May 16	May 15
# Analysts	2	2	1	-	1	4	1	-	1	14	10	10	7	12	7	6	3	3	6	9	17	8	19
SG&A	-	-	-	-	-	-	-	-	-	-	$3.56M	$3.63M	$3.28M	-	$3.07M	$3.42M	$3.25M	-	$2.90M	-	$2.70M	-	-
Avg Forecast	$30.26M	$18.15M	$12.10M	-	$4.48M	$19.90M	$552.99K	-	$4.76M	$448.37K	$1.28M	$667.22K	$1.60M	$2.02M	$10.76M	$3.49M	$3.44M	$3.89M	$4.54M	$659.92K	$123.50K	$7.90K	$284.78K
High Forecast	$54.11M	$32.46M	$21.64M	-	$8.01M	$35.58M	$988.89K	-	$8.51M	$538.04K	$1.28M	$667.22K	$1.60M	$2.02M	$10.76M	$3.49M	$3.44M	$4.66M	$4.54M	$791.90K	$148.20K	$9.48K	$341.74K
Low Forecast	$6.41M	$3.84M	$2.56M	-	$948.56K	$4.21M	$117.08K	-	$1.01M	$358.70K	$1.28M	$667.22K	$1.60M	$2.02M	$10.76M	$3.49M	$3.44M	$3.11M	$4.54M	$527.93K	$98.80K	$6.32K	$227.82K
Surprise %	-	-	-	-	-	-	-	-	-	-	2.78%	5.44%	2.05%	-	0.29%	0.98%	0.94%	-	0.64%	-	21.89%	-	-

KalVista Pharmaceuticals's average Quarter SG&A projection for May 21 is $448.37K, based on 14 Wall Street analysts, with a range of $358.70K to $538.04K. The forecast indicates a -87.41% fall compared to KALV last annual SG&A of $3.56M (Jan 21).

KalVista Pharmaceuticals EPS Forecast

	May 26	Jan 26	Oct 25	Jul 25	May 25	Jan 25	Oct 24	Jul 24	May 24	May 21	Jan 21	Oct 20	Jul 20	May 20	Jan 20	Oct 19	Jul 19	May 19	Jan 19	May 18	Oct 17	May 16	May 15
# Analysts	2	2	1	-	1	4	1	-	1	14	10	10	7	12	7	6	3	3	6	9	17	8	19
EPS	-	-	-	-	-	-	-	-	-	-	$-0.39	$-0.44	$-0.36	-	$-0.30	$-0.11	$-0.32	-	$-0.06	-	$-0.40	-	-
Avg Forecast	$-0.54	$-0.71	$-0.75	$-0.88	$-0.81	$-0.65	$-0.93	$-0.92	$-0.71	$-0.53	$-0.60	$-0.67	$-0.60	$-0.65	$-0.26	$-0.55	$-0.62	$-0.35	$-0.45	$-0.21	$-0.67	$-1.68	$-88.79
High Forecast	$0.01	$0.02	$0.02	$0.02	$0.02	$1.12	$-0.92	$0.02	$0.02	$-0.53	$-0.60	$-0.67	$-0.60	$-0.65	$-0.26	$-0.55	$-0.62	$-0.35	$-0.45	$-0.17	$-0.54	$-1.34	$-71.04
Low Forecast	$-1.09	$-1.44	$-1.52	$-1.78	$-1.63	$-1.47	$-0.95	$-1.85	$-1.44	$-0.53	$-0.60	$-0.67	$-0.60	$-0.65	$-0.26	$-0.55	$-0.62	$-0.35	$-0.45	$-0.25	$-0.80	$-2.02	$-106.55
Surprise %	-	-	-	-	-	-	-	-	-	-	0.65%	0.66%	0.60%	-	1.15%	0.20%	0.52%	-	0.13%	-	0.60%	-	-

According to undefined Wall Street analysts, KalVista Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KALV previous annual EPS of $NaN (undefined).

KalVista Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GOSS	Gossamer Bio	$0.66	$3.75	468.18%	Buy
LRMR	Larimar Therapeutics	$6.13	$20.33	231.65%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
KURA	Kura Oncology	$10.06	$26.00	158.45%	Buy
CGEM	Cullinan Oncology	$12.22	$31.50	157.77%	Buy
KALV	KalVista Pharmaceuticals	$9.33	$22.67	142.98%	Buy
IMCR	Immunocore	$32.12	$70.75	120.27%	Buy
SNDX	Syndax Pharmaceuticals	$15.60	$34.30	119.87%	Buy
REPL	Replimune Group	$11.05	$24.20	119.00%	Buy
COGT	Cogent Biosciences	$8.98	$18.83	109.69%	Buy
VRDN	Viridian Therapeutics	$19.62	$37.92	93.27%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
CYTK	Cytokinetics	$47.67	$83.23	74.60%	Buy
MRSN	Mersana Therapeutics	$1.98	$3.00	51.52%	Buy
DYN	Dyne Therapeutics	$29.73	$43.88	47.60%	Buy
EWTX	Edgewise Therapeutics	$31.98	$45.00	40.71%	Buy
MIRM	Mirum Pharmaceuticals	$43.48	$57.25	31.67%	Buy
DICE	DICE Therapeutics	$47.55	$60.00	26.18%	Buy
CRNX	Crinetics Pharmaceuticals	$57.03	$70.14	22.99%	Buy
KRTX	Karuna Therapeutics	$329.83	$257.50	-21.93%	Buy

KALV Forecast FAQ

Is KalVista Pharmaceuticals a good buy?

Yes, according to 4 Wall Street analysts, KalVista Pharmaceuticals (KALV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of KALV's total ratings.

What is KALV's price target?

KalVista Pharmaceuticals (KALV) average price target is $22.67 with a range of $20 to $28, implying a 143.24% from its last price of $9.32. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will KalVista Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for KALV stock, the company can go up by 143.24% (from the last price of $9.32 to the average price target of $22.67), up by 200.43% based on the highest stock price target, and up by 114.59% based on the lowest stock price target.

Can KalVista Pharmaceuticals stock reach $14?

KALV's average twelve months analyst stock price target of $22.67 supports the claim that KalVista Pharmaceuticals can reach $14 in the near future.

What is KalVista Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $28 price target for KalVista Pharmaceuticals (KALV) this month, up 200.43% from its last price of $9.32. Compared to the last 3 and 12 months, the average price target increased by 143.24% and increased by 143.24%, respectively.

Did the KALV's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Jan 2020), KalVista Pharmaceuticals's revenue was $1.58M, missing the average analysts' forecast of $10.08M by -84.35%. The company's EBITDA was $-12.583M, missing the average prediction of $2.02M by -724.30%. KalVista Pharmaceuticals's net income was $-9.291M, missing the average estimation of $-12.087M by -23.13%. The company's SG&A was $3.07M, missing the average forecast of $10.76M by -71.48%. Lastly, the company's EPS was $-0.3, beating the average prediction of $-0.261 by 14.75%